Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons

Nature Medicine

Volumn 2, Issue 9, 1996, Pages 1017-1021

  Hantraye, Philippe ^a   Brouillet, Emmanuel ^a   Ferrante, Robert ^b,c   Palfi, Stéphane ^a   Dolan, Robert ^a   Matthews, Russell T ^d,e   Beal, M Flint ^d,e  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 7 NITROINDAZOLE; NITRIC OXIDE SYNTHASE INHIBITOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; ENZYME INHIBITORS; HOMOVANILLIC ACID; HYPOKINESIA; INDAZOLES; MALE; MOTOR ACTIVITY; NEUROLOGIC EXAMINATION; NEURONS; NITRIC OXIDE SYNTHASE; PAPIO; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; VIDEOTAPE RECORDING;

ANIMALIA; PAPIO; PAPIO HAMADRYAS;

EID: 0029844003     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0996-1017     Document Type: Article

References (29)

1. Burns, R.S. et al. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546-4550 (1983).
2. Bloem, B.R. et al. The MPTP model: Versatile contributions to the treatment of adiopathic Parkinson's disease J Neurol. Sci. 97, 273-293 (1990).
3. Langston, J.W., Ballard, P , Tetrud, J.W. & Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 219, 979-980 (1983).
4. Hantraye, P. et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibers following chronic MPTP administration in baboons. Neuroscience 53, 169-178 (1993).
5. Varastet, M , Riche, D., Mazière, M & Hantraye, P. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 63, 47-56 (1994).
6. Forno, L.S., Langston, J.W., DeLanney, L.E., Irwin, I. & Ricaurte, G.A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20, 449-455 (1986).
7. Tipton, K F. & Singer, T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206 (1993).
8. Beal, M.F. Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357-366 (1995).
9. Dawson, V.L. et al. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures Proc. Natl. Acad. Sci. USA 88, 6368-6371 (1991).
10. Dawson, V.L et al. Mechanisms of nitric oxide mediated neurotoxicity in primary brain cultures. J. Neurosci. 13, 2651-2661 (1993)
11. Schulz, J B., Matthews, R.T., Muqit, M M.K., Browne, S.E. & Beal, M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64, 936-939 (1995a).
12. Przedborski, S. et al. Role of nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA 93, 4565-4571 (1996).
13. German, D C., Dubach, M., Askari, S., Speciale, S.G. & Bowden, D.M. 1-Methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-induced parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost? Neuroscience 24, 161-174 (1988).
14. Schneider, J.S. Behavioral and neuropathological consequences of chronic exposure to low doses of the dopaminergic neurotoxin MPTP. in The Vulnerable Brain and Environmental Risks (eds. Isaacson, R.L. & Jensen, K.F.) 293-308 (Plenum, New York, 1992).
15. Lipton, S.A. et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds Nature 364, 626-632 (1993).
16. Schulz, J.B. et al. Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J. Neurosci. 15, 8419-8429 (1995b).
17. Beckman, J.S. et al. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch. Biochem. Biophys. 298, 438-445 (1992).
18. Ischiropoulos, H. et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298, 431-437 (1992).
19. Wolff, D.J. & Gribin, B.J. The inhibition of the constitutive and inducible nitric oxide synthase isoforms by indazole agents Arch. Biochem. Biophys. 311, 300-306 (1994).
20. Babbedge, R.C et al. Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br. J. Pharmacol. 110, 225-228 (1993).
21. Przedborski, S. et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12, 1658-1667 (1992).
22. Diamond, A. Developmental time course in human infants and infant monkeys, and the neural bases of inhibitory control in reaching. Ann. N.Y. Acad. Sci. 608, 637-669 (1990).
23. Palfi, S. et al. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington disease J. Neurosci. (in the press)
24. Lin, A.M -Y., Kao, L.-S. & Chai, C.Y. Involvement of nitric oxide in dopaminergic transmission in rat striatum: An in vivo electrochemical study. J. Neurochem 65, 2043-2049 (1995).
25. 3H]glutamate by striatal synaptosomes. J. Neurochem. 63, 2108-2117 (1994).
26. Silva, M.T. et al. Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole. Br. J. Pharmacol. 114, 257-258 (1995).
27. Brouillet, E. et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates Proc. Natl. Acad. Sci USA 92, 7105-7109 (1995)
28. Beal, M.F., Kowall, N.W., Swartz, K.J. & Ferrante, R. Homocysteic acid striatal lesions in rats spare somatostatin-neuropeptide Y neurons. Neurosci Lett. 108, 36-42 (1990).
29. Ferrante, R J., Kowall, N W., Cipolloni, P.B., Storey, E. & Beal, M F Excitotoxin lesions in primates as a model of Huntington's disease: Histopathologic and neurochemical characterization. Exp. Neurol. 119, 46-71 (1993).